Drug intelligence / Profile preview

cefuroxime + flucloxacillin + metronidazole

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

This is a combination regimen of three antibiotics—cefuroxime, flucloxacillin, and metronidazole—used together for broad-spectrum antibacterial coverage. - **Cefuroxime** is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, effective against many Gram-positive and some Gram-negative bacteria[8]. - **Flucloxacillin** is a narrow-spectrum beta-lactam antibiotic (penicillin class) that targets mainly Gram-positive organisms, especially Staphylococcus aureus (including penicillinase-producing strains), by inhibiting cell wall synthesis. - **Metronidazole** is an antimicrobial agent particularly active against anaerobic bacteria and certain protozoa; it disrupts DNA synthesis in susceptible organisms[7]. The combination provides comprehensive coverage for mixed infections involving aerobic Gram-positive cocci (notably staphylococci), some Gram-negative bacilli, and anaerobes. It may be used as empirical therapy in surgical prophylaxis or treatment of polymicrobial infections such as intra-abdominal sepsis or complicated skin/soft tissue infections where both aerobic and anaerobic pathogens are likely to be present[4][5][9].

02

Targets

PBP (Penicillin-binding protein family)Neuraminidase

Beyond the preview

Go deeper on cefuroxime + flucloxacillin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefuroxime + flucloxacillin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call